secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cidara Therapeutics, Inc. (—)
CIK:        0001610618
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-005517
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck completes acquisition of Cidara Therapeutics for $221.50 per share
------------------------------------------------------------------------

- Tender offer expired Jan 6 with 27,149,333 common shares and 89,956 Series A shares validly tendered, representing ~88.3% of total voting shares.
- Each common share converted to $221.50 cash; each Series A share converted to $15,505.00 cash, without interest.
- Common shares delisted from Nasdaq effective Jan 7; company will file Form 15 to terminate SEC registration and reporting obligations.
- Board replaced by Merck designees Jon Filderman, Melissa Leonard, Dalton Smart; prior directors resigned.
- Company's equity incentive plans and stock purchase plan terminated at the Effective Time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610618/000119312526005517/0001193125-26-005517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610618/000119312526005517/d57313d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-005517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer